Kurzius Lawrence Erik

10% owner Kurzius Lawrence Erik sold 50,000 shares of MKC at $71.63 for $3.6M on 2026-02-12.

Kurzius, a 10% owner, sold 50,000 shares (50.0K shares) at $71.63, reducing his position from 346,992 shares to 297.0K shares—a -14.4% decrease in holdings. At the current price of $71.49, the stock is -15.6% from its 52-week high of $84.73, though it has risen 4.3% over the past 30 days and 9.4% over 90 days. Looking at his prior MKC trades, Kurzius's 4 measurable prior sales at this ticker generated positive 90-day returns (averaging +5.1%), meaning the stock rose after those sales—a 0% well-timed rate at MKC. His cross-ticker track record on sells shows a 27.27% well-timed rate across 12 prior sales, with an average 90-day return of +2.7%, suggesting below-average timing precision on his recent transactions. With MKC trading at a P/E of 24.32 and posting annual revenue growth of +1.7% ($1.7B in latest quarterly revenue), the sale represents a moderate-sized position reduction by a principal shareholder, though the stock's modest gains in recent weeks and proximity to recent sales warrant monitoring of broader insider activity.

10% owner Kurzius sold 50,000 MKC shares at $67.43; reduces stake by 16.8% while stock trades 19.1% below 52-week high.

Kurzius Lawrence Erik, a 10% owner, sold 50,000 shares (246.8K shares) of McCormick & Co for $3.4M on 2026-01-13, reducing his post-transaction holdings to 246.8K shares from 296.8K shares—a 16.8% reduction in stake. The sale occurred at $67.43, while the stock currently trades at $68.57, down 19.1% from its 52-week high of $84.73. Prior to this transaction, Kurzius's cross-ticker track record showed 11 prior sells with a 50.00% well-timed rate and a 90-day average return of +0.7%. At MKC specifically, all 5 prior measurable trades were sales executed on 2025-11-11, which subsequently showed +2.2% 30-day returns, though 90-day outcomes remain unmeasurable. The company's fundamentals show annual revenue growth of +0.9% with a P/E of 23.32. This sale occurs alongside a stock positioned near its lows relative to recent highs, but without additional context from FLAGS or scheduled trading plans, the transaction stands as a discretionary large reduction in a major shareholder's position.

Director Kurzius Lawrence Erik bought 2,000 shares (2.0K) of COO at $82.50 on 2025-12-17; part of cluster with 2 other insiders buying within 14 days

Director Kurzius Lawrence Erik purchased 2,000 shares valued at $165,000.00, increasing his holdings by 34.6% from 5,777 to 7,777 shares. This transaction occurs as part of a cluster buy pattern, with 2 other insiders also buying within the past 14 days, which may indicate coordinated confidence in the company's direction. Across his cross-ticker track record, his prior buys have averaged a 90d return of +29.8% with a 100.00% win rate, though his same-ticker history at COO shows only one prior measurable trade (a September buy with +1.7% 30d return). The stock currently trades at $82.48, down 17.1% from its 52-week high of $99.45 but up 22.7% over 90 days, positioning this purchase near recent strength despite distance from the year's peak.

Director Kurzius Erik purchases 10,000 shares of ELAN at $21.30; cluster of 4 insiders buying within 14 days as stock rallies 22.0% in 90 days

Kurzius Lawrence Erik, a Director at Elanco Animal Health, purchased 10,000 shares at $21.30 on 2025-12-12, increasing his holdings to 131,773 shares. This transaction is part of a cluster buy pattern, with 3 other insiders also purchasing shares within the past 14 days. Kurzius's prior trades at ELAN show a strong timing pattern: both prior buys (on 2025-03-11 and 2025-03-07) delivered positive 90-day returns of +36.5% and +23.2% respectively. The current environment is favorable—ELAN has rallied 22.0% over 90 days and 6.6% over 30 days, and is trading near its 52-week high at $22.49 versus a 52-week range of $8.10–$23.43. However, the company's fundamentals remain challenged: net income is -$34.0M on $1.1B quarterly revenue, with minimal annual revenue growth of +0.5% and a P/E ratio of 321.29, reflecting an unprofitable or extremely low-margin business. The cluster buying signal and Kurzius's historical buying track record at this ticker warrant investor attention to whether insiders perceive value or upcoming catalysts not yet reflected in public data.

10% Owner Kurzius Lawrence Erik sells entire 39.0K share stake for $2.5M at $64.54

Kurzius Lawrence Erik, a 10% owner of McCormick & Co (MKC), executed 5 separate sales on 2025-11-11 totaling 39,014 shares for $2,517,963.56 at $64.54, liquidating his entire remaining position to zero shares. The current stock price of $65.88 sits 22.2% below its 52-week high of $84.73, and his transaction price of $64.54 is near the current market level. This complete liquidation is material given his 10% stakeholder status—such full exits by major shareholders typically warrant investor attention. His prior sell activity at MKC shows mixed timing: 2 of 4 prior measurable sales were well-timed (90d return negative, meaning he sold before declines), though 2 were poorly timed (stock rose after the sale). The company's annualized fundamentals show modest growth (Revenue $1.7B, +0.9% annual growth) and a P/E of 22.41, providing context for valuation at the time of the sale.

10% owner sold 50,000 MKC shares at $65.86; down -21.3% from 52-week high; 3 of 5 prior MKC sales well-timed

Kurzius Lawrence Erik, holding 246.8K shares post-transaction, sold 50,000 shares (16.8% of pre-transaction holdings) at $65.86 on 2025-10-08 for $3.3M. The stock is currently trading at $66.66, already 30 basis points above the sale price, but remains 21.3% below its 52-week high of $84.73. Examining his prior trades at MKC specifically, 3 of 5 previous sales showed negative 90-day returns, indicating a 60% well-timed rate on this ticker—meaningfully above the baseline but not conclusive. His cross-ticker track record on sells shows an average 90-day return of 0.7% (well-timed rate 60.00%), suggesting neither consistent precision nor systematic misjudgment in execution timing. The company's fundamentals remain solid with revenue of $1,724,900,000.00 and net income of $225,500,000.00 in the latest quarter, though annual revenue growth of 0.9% reflects a stalled business. The sale itself reduces his exposure but leaves him with substantial holdings, suggesting this is a partial liquidation rather than a complete exit signal.

Director Kurzius buys 2,000 shares of COO at $68.39; holdings rise 53.0% to 5,777 shares

Kurzius Lawrence Erik, a Director, purchased 2,000 shares at $68.39, raising his total holdings from 3,777 to 5,777 shares—a 53.0% increase in position size. The purchase occurs with the stock trading at $67.67, below its 52-week high of $110.34 by 38.7%, though up slightly on a 30-day basis (+0.4%) and down 7.1% over 90 days. Historically across all tickers, this insider's prior buys have posted weak returns (average -7.9% over 90 days with a 0.00% win rate), and his sell timing has been more reliable (60.00% well-timed rate). The company shows solid fundamentals with $1.1B in latest quarterly revenue, $98.3M in net income, and 8.4% annual growth; the P/E of 33.01 reflects a premium valuation relative to the broader market. The transaction reveals a discretionary accumulation despite the insider's mixed track record on buy-side timing.

MKC: Director Kurzius sold 50,000 shares at $81.81 for $4.1M, reducing stake to 247.4K shares (-16.8%)

Director Kurzius Erik sold 50,000 shares of McCormick & Co at $81.81 on April 2, 2025, reducing his holdings from 297.4K shares to 247.4K shares. The sale price of $81.81 is near the 52-week high of $84.76 and above the current price of $81.29. Across his four prior sales at MKC, only one of three measurable outcomes (33%) was well-timed when the stock subsequently declined; his most recent MKC sell on 2025-02-03 showed a 30-day gain of +7.7%, indicating the stock rose after that sale. The company's fundamentals show annual revenue growth of only +0.9% with a P/E of 27.65, suggesting limited organic momentum. This sale represents a meaningful 16.8% reduction in the insider's MKC holdings but does not materially distinguish itself from his prior trading pattern at this ticker.

Elanco director Kurzius purchased 20,000 shares for $211,000.00 across two trades; stock down 45.6% from 52-week high.

Kurzius Lawrence Erik, a director at Elanco Animal Health Inc (ELAN), made two separate open-market purchases totaling 20,000 shares for $211,000.00 in early March 2025, with a blended average price of $10.55. His holdings increased 21.9% from 91,459 to 111,459 shares. The timing of these purchases is notable: ELAN's stock is currently priced at $10.04, approximately 45.6% below its 52-week high of $18.45, and down 19.9% over the last 90 days. The company reports strong fundamentals with $1.0B in quarterly revenue and a notably low P/E of 2.80. However, the director's cross-ticker track record shows modest performance with a 90-day well-timed sale rate of 33.33%, suggesting his prior market timing has been mixed. The substantial markdown from the 52-week high warrants attention to whether this accumulation reflects opportunistic positioning in a depressed market or other considerations.

Director Kurzius Lawrence Erik sold 50,000 MKC shares at $76.81 on 2025-02-03 for $3.8M, reducing holdings to 276.9K shares.

Director Kurzius sold 50,000 shares (15.3% reduction from pre-transaction holdings of 326.9K shares) at $76.81, while the stock currently trades at $76.88 and sits 9.3% below its 52-week high of $84.76. His cross-ticker track record shows 3 prior sells with mixed timing results: 90-day well-timed rate of 33.33% indicates only 1 of 3 prior open-market sells were well-timed. At MKC specifically, his prior 3 sales produced 90-day returns of +8.6%, +6.0%, and -4.3%, with only 1 of 3 well-timed at the 90-day mark. The company's fundamentals show modest revenue growth of +0.9% year-over-year against a P/E of 26.15, with latest quarterly revenue of $1.7B and net income of $223.1M. This sale reduces but does not eliminate his substantial remaining stake, suggesting selective rather than complete portfolio exit.